Relevant bibliographies by topics / Stage III NSCLC

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Stage III NSCLC'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Stage III NSCLC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Stage III NSCLC"

1

Recondo, Gonzalo, Robin Guo, Paola Cravero, et al. "Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): 9042. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.9042.

Full text
Abstract:
9042 Background: MET exon 14 alterations occur in ~3% of patients (pts) with NSCLC. Although clinical and genomic features of MET exon 14 mutant (mut) NSCLC are better characterized in the metastatic setting, less is known about early-stage disease for this molecular subtype. Methods: Clinicopathologic and genomic data were collected from patients (pts) with resected stage I-III MET exon 14 mutant NSCLC at the Dana-Farber Cancer Institute (DFCI) and the Memorial Sloan Kettering Cancer Center (MSKCC). We estimated the disease-free survival (DFS) and overall survival (OS) of patients from the da
APA, Harvard, Vancouver, ISO, and other styles
2

Narukurthi, Ravi Kiran, Nallamothu Murali Krishna, Jetty Mounika, and T. Jaya Chandra. "Clinical response to chemotherapy in non-small cell lung carcinoma patients." International Journal of Research in Medical Sciences 7, no. 12 (2019): 4641. http://dx.doi.org/10.18203/2320-6012.ijrms20195531.

Full text
Abstract:
Background: Lung carcinoma is the most common. With this, a study was conducted to assess the clinical profile of Non-small cell lung carcinoma (NSCLC) and also to evaluate the response to chemotherapy in various stages of NSCLC.Methods: It was a prospective study. All the clinically confirmed cases with NSCLC were taken into consideration. Clinical staging was done, diagnosis was confirmed by histopathological findings. Treatment was given depending on the stage of carcinoma. Patients were evaluated before each cycle of chemotherapy for any progression of disease. Pathological response was ev
APA, Harvard, Vancouver, ISO, and other styles
3

Allen, Jeffrey, and Mohammad Jahanzeb. "Neoadjuvant Chemotherapy in Stage III NSCLC." Journal of the National Comprehensive Cancer Network 6, no. 3 (2008): 285–93. http://dx.doi.org/10.6004/jnccn.2008.0024.

Full text
Abstract:
Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer-related mortality in the United States. Current standard care for treating NSCLC is surgical resection, when feasible, followed by adjuvant chemotherapy in stages II and III. Neoadjuvant or induction chemotherapy may have several potential advantages compared with adjuvant chemotherapy and has been evaluated in randomized and nonrandomized clinical trials in NSCLC. This article reviews the data for neoadjuvant chemotherapy in NSCLC with a particular focus on regionally advanced disease (stage III) that is still amen
APA, Harvard, Vancouver, ISO, and other styles
4

Sathiyapalan, Arani, Ziad Baloush, and Peter M. Ellis. "Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease." Current Oncology 30, no. 11 (2023): 9514–29. http://dx.doi.org/10.3390/curroncol30110689.

Full text
Abstract:
Background: Stage III nonsmall cell lung cancer (NSCLC) represents a heterogeneous group of patients. Many patients are treated with curative intent multimodality therapy, either surgical resection plus systemic therapy or chemoradiation plus immunotherapy. However, many patients are not suitable for curative intent therapy and are treated with palliative systemic therapy or best supportive care. Methods: This paper is a review of recent advances in the management of patients with curative intent disease. Results: There have been significant advances in curative intent therapy for patients wit
APA, Harvard, Vancouver, ISO, and other styles
5

An, Josiah, Melissa Yan, Nanmeng Yu, et al. "Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation." Journal of Clinical Oncology 38, no. 15_suppl (2020): 9033. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.9033.

Full text
Abstract:
9033 Background: STK11 mutation ( STK11m) in patients with stage IV NSCLC is associated with inferior survival and poor response to immune check point inhibitors (ICI). The significance of STK11m in patients (pts) with stage III NSCLC treated with concurrent chemoradiation (CCRT) with and without consolidation ICI is unknown. Methods: Patient demographics, disease characteristics, treatment received and outcomes in pts with stage III NSCLC that harbor STK11m were retrospectively reviewed from 4 cancer centers. A cohort of pts with stage III NSCLC and wild type STK11 (STK11w) from the Universit
APA, Harvard, Vancouver, ISO, and other styles
6

Deslypere, Griet, Dorothée Gullentops, Els Wauters, and Johan Vansteenkiste. "Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?" Therapeutic Advances in Medical Oncology 10 (January 1, 2018): 175883591877281. http://dx.doi.org/10.1177/1758835918772810.

Full text
Abstract:
Over the last decade, several steps forward in the treatment of patients with stage IV non-small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kinase inhibitors in patients selected on the basis of an activating oncogene, such as epidermal growth factor receptor ( EGFR) activating mutations or anaplastic lymphoma kinase ( ALK) translocations. However, all of these achievements could not be translated into survival benefits when studied in rand
APA, Harvard, Vancouver, ISO, and other styles
7

Al-Shamsi, Humaid Obaid, and Peter Michael Ellis. "Stage III NSCLC: How many patients are really suitable for radical treatment approaches?" Journal of Clinical Oncology 30, no. 15_suppl (2012): e17532-e17532. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e17532.

Full text
Abstract:
e17532 Background: Stage III NSCLC represents a heterogeneous population. Patients with good performance status (PS) and weight loss < 10% (WL<10) are generally considered for radical treatment with chemoradiation or trimodality approaches. Outcome data from Cancer Care Ontario show 30% of stage III NSCLC (6th edition TNM) patients receive chemoradiation.There is significant variation between local health networks. We examined the proportion of patients with stage III NSCLC suitable for radical treatment. Methods: We conducted a retrospective cohort study of patients diagnosed with stage
APA, Harvard, Vancouver, ISO, and other styles
8

Williams, Christina D., Ajeet Gajra, Apar Kishor Ganti, and Michael J. Kelley. "Utilization and impact of adjuvant chemotherapy (AC) in surgically resected stages I-III non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, no. 15_suppl (2013): 7538. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7538.

Full text
Abstract:
7538 Background: Clinical trials demonstrating improved survival with AC for stages I-III NSCLC are limited in their applicability to broader populations. We sought to describe the pattern of AC use and its correlation with survival in the population-based VA system. Methods: We conducted a retrospective analysis of pts with stages I-III NSCLC in the VA Central Cancer Registry. Descriptive statistics were used to examine patterns of AC use over an 8 yr period and to obtain survival rates associated with use of AC. Chi-square was used to compare distributions. Results: Among 28,173 pts with sta
APA, Harvard, Vancouver, ISO, and other styles
9

Soo, Ross A., Thanyanan Reungwetwattana, Herman Andres Perroud, et al. "Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study." Journal of Clinical Oncology 41, no. 16_suppl (2023): 8531. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.8531.

Full text
Abstract:
8531 Background: The prevalence of EGFR mutations ( EGFRm) in resected stage I-III NSCLC remains controversial as prior research studies were retrospective in nature. EARLY-EGFR is the first prospective, international study to determine the prevalence of EGFRm and treatment patterns in patients (pts) with early-stage NSCLC. Methods: EARLY-EGFR (NCT04742192), a non-interventional real-world study, captured data on EGFRm status, treatment patterns, demographic, clinical and pathological characteristics in consecutively enrolled pts with surgically resected stage IA-IIIB (AJCC 8th) non-squamous N
APA, Harvard, Vancouver, ISO, and other styles
10

Alessi, Joao V., Adam Price, Allison L. Richards, et al. "Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer." Journal for ImmunoTherapy of Cancer 11, no. 11 (2023): e007618. http://dx.doi.org/10.1136/jitc-2023-007618.

Full text
Abstract:
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III NSCLC treated with concurrent chemoradiation (cCRT) and durvalumab consolidation, we identify that low tumor aneuploidy is independently associated with prolonged progression-free survival (HR 0.63; p=0.03) and overall survival (HR 0.50; p=0.03). Tumors with high aneuploidy had a significantly greater incidence of distant metastasis and shorter median distant-metastasis free survival (p=0.04 and p=0.0
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Stage III NSCLC"

1

Felip, E., N. K. Altorki, C. Zhou, et al. "Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study." Thesis, Elsevier, 2022. https://essuir.sumdu.edu.ua/handle/123456789/87802.

Full text
Abstract:
IMpower010 showed significant DFS benefit with atezo after adjuvant chemo in resected NSCLC (Felip Lancet 2021). At the interim DFS analysis, the significance boundary was crossed for the stage II-IIIA PD-L1 TC 1% population (stratified HR, 0.66; 95% CI: 0.50, 0.88), with greatest benefit in the PD-L1 TC 50% subgroup (unstratified HR, 0.43; 95% CI: 0.27, 0.68). Here we present further analyses in PD-L1 TC 50% stage II-IIIA NSCLC pts.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Stage III NSCLC"

1

Hecker, E., H. Hoffmann, A. Kraft, and H. Dienemann. "Broncho- und angioplastische Eingriffe nach Induktionstherapie des nicht-kleinzelligen Bronchialcarcinoms (NSCLC) im Stadium III / Sleeve Resection after Induction Chemotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC)." In Deutsche Gesellschaft für Chirurgie. Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56458-1_216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fleck, J., D. Godoy, and J. Camargo. "High incidence of CNS metastases in long-term survivors (LTS) stage III (T4/N2) non-small cell lung cancer (NSCLC). Patients treated with Neo-Adjuvant chemotherapy." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy. Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Koubek, Richard D., and Sumedh S. Hoskote. "A 74-Year-Old Man With a Pulmonary Nodule and Neck Pain." In Mayo Clinic Case Review for Pulmonary and Critical Care Boards, edited by Eric S. Edell and Tobias Peikert. Oxford University PressNew York, 2023. http://dx.doi.org/10.1093/med/9780197755877.003.0032.

Full text
Abstract:
Abstract FDG-avid pulmonary nodules with mediastinal or hilar lymph nodes on PET-CT can have malignant or benign origins. Certain characteristics of the nodule appearance and FDG uptake patterns can help guide consideration for a malignant basis in the appropriate clinical context. Non–small cell lung cancer (NSCLC) with ipsiliateral mediastinal lymph node involvement is considered N2 disease and indicates NSCLC that is at least stage IIIA. Treatment of stage III disease is best coordinated with a multidisciplinary team because of the complexity of the decisions involved and the broad spectrum
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Stage III NSCLC"

1

Dooper, Marten. "Consolidation therapy with benmelstobart in stage III NSCLC." In ASCO Annual Meeting 2025, edited by Stefan Rauh. Medicom Medical Publishers, 2025. https://doi.org/10.55788/4b8d5799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Garassino, Marina, and Marten Dooper. "Durvalumab after sequential CRT safe in stage III, unresectable NSCLC." In European Lung Cancer Congress 2022, edited by Stefan Rauh. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/40806c98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gutiontov, Stanley I., and Sean Pitroda. "Abstract 799: CDKN2A mutation predicts immunotherapy resistance in stage III/IV NSCLC." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-799.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Muehling, BM, F. Kanz, J. Haeberlin, P. Xu, A. Babiak, and C. Babiak. "P15 Surgical resection results in prolonged survival in patients with stage III NSCLC." In British Thoracic Society Winter Meeting 2023, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 22 to 24 November 2023, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2023. http://dx.doi.org/10.1136/thorax-2023-btsabstracts.167.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dooper, Marten. "Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC." In ASCO Annual Meeting 2024, edited by Stefan Rauh. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/a63eb2ba.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yang, Yunpeng, and Marten Dooper. "Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC." In European Lung Cancer Congress 2022, edited by Stefan Rauh. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/4c88e56b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Luna Castaneda, Jose M., Andrew Barsky, Russell T. Shinohara, et al. "Radiomic features predict local failure-free survival in stage III NSCLC adenocarcinoma treated with chemoradiation." In Computer-Aided Diagnosis, edited by Karen Drukker and Maciej A. Mazurowski. SPIE, 2021. http://dx.doi.org/10.1117/12.2581873.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

de Wit, M., C. Schulz, HE Laack, et al. "Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC." In 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Faehling, M., C. Schulz, H. Laack, et al. "PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT." In 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

hadidene, yasmine, Hela Kamoun, Azza Slim, et al. "Performance status and body mass index : prognosis impact of their changes in patients with stage III NSCLC." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1639.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Stage III NSCLC"

1

Sriuranpong, Virote. The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable nonmetastasis NSCLC as a prognostic marker of disease. Chulalongkorn University, 2010. https://doi.org/10.58837/chula.res.2010.16.

Full text
Abstract:
Introduction; Despite adequate surgical management of stage I non-small cell lung cancer, many patients still have relapsed of disease which leads to mortality. Micrometastasis of tumor is the postulate mechanism which might not be detected by standard H&E method. The author conducted the study of epithelial methylation marker, SHP-1 Promoter 2 (SHP1P2) methylation as a potential molecular marker to detect high risk relapsed of disease in stage I resectable non-small cell lung cancer (NSCLC). Method; To explore the potential role of SHP1P2 methylation to detect micrometastasis, Lymph node
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Stage III NSCLC' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography